HC Wainwright Reaffirms Buy Rating for Coherus BioSciences (NASDAQ:CHRS)

HC Wainwright restated their buy rating on shares of Coherus BioSciences (NASDAQ:CHRSFree Report) in a report issued on Friday, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the biotechnology company’s stock.

Separately, Truist Financial lowered their price objective on shares of Coherus BioSciences from $8.00 to $7.00 and set a buy rating for the company in a research note on Monday, May 13th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $8.83.

View Our Latest Stock Report on Coherus BioSciences

Coherus BioSciences Price Performance

CHRS stock traded down $0.10 during mid-day trading on Friday, hitting $1.91. The stock had a trading volume of 1,444,636 shares, compared to its average volume of 1,703,285. Coherus BioSciences has a 52 week low of $1.43 and a 52 week high of $5.63. The firm has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $2.30.

Coherus BioSciences (NASDAQ:CHRSGet Free Report) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The business had revenue of $77.06 million for the quarter, compared to analysts’ expectations of $102.00 million. During the same quarter in the prior year, the company posted ($0.89) earnings per share. On average, analysts anticipate that Coherus BioSciences will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Coherus BioSciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dorsey & Whitney Trust CO LLC purchased a new position in Coherus BioSciences in the third quarter worth about $39,000. TrinityPoint Wealth LLC bought a new position in shares of Coherus BioSciences during the 4th quarter valued at approximately $40,000. China Universal Asset Management Co. Ltd. increased its position in shares of Coherus BioSciences by 430.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 10,454 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new position in shares of Coherus BioSciences during the 4th quarter valued at approximately $47,000. Finally, Vontobel Holding Ltd. bought a new position in shares of Coherus BioSciences during the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

About Coherus BioSciences

(Get Free Report)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

See Also

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.